Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes

Background and Purpose— The SPARCL trial showed that atorvastatin 80 mg/d reduces the risk of stroke and other cardiovascular events in patients with recent stroke or transient ischemic attack (TIA). We tested the hypothesis that the benefit of treatment varies according to index event stroke subtype. Methods— Subjects with stroke or TIA without known coronary heart disease were randomized to atorvastatin 80 mg/d or placebo. The SPARCL primary end point was fatal or nonfatal stroke. Secondary end points included major cardiovascular events (MCVE; stroke plus major coronary events). Cox regression models testing for an interaction with treatment assignment were used to explore potential differences in efficacy based on stroke subtype. Results— For subjects randomized to atorvastatin versus placebo, a primary end point occurred in 13.1% versus 18.6% of those classified as having large vessel disease (LVD, 15.8% of 4,731 participants), in 13.1% versus 15.5% of those with small vessel disease (SVD, 29.8%), in 11.2% versus 12.7% of those with ischemic stroke of unknown cause (21.5%), in 7.6% versus 8.8% of those with TIA (30.9%), and in 22.2% versus 8.3% of those with hemorrhagic stroke (HS, 2%) at baseline. There was no difference in the efficacy of treatment for either the primary end point (LVD hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.49 to 1.02, TIA HR 0.81, CI 0.57 to 1.17, SVD HR 0.85, CI 0.64 to 1.12, unknown cause HR 0.87, CI 0.61 to 1.24, HS HR 3.24, CI 1.01 to 10.4; P for heterogeneity=0.421), or MCVEs (P for heterogeneity=0.360) based on subtype of the index event. As compared to subjects with LVD strokes, those with SVD had similar MCVE rates (19.2% versus 18.5% over the course of the trial), and similar overall reductions in stroke and MCVEs. Conclusions— Atorvastatin 80 mg/d is similarly efficacious in preventing strokes and other cardiovascular events, irrespective of baseline ischemic stroke subtype.

[1]  R. Sacco,et al.  Antithrombotic and thrombolytic therapy for ischemic stroke. , 1998, Chest.

[2]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[3]  J. Hauw,et al.  Autopsy Prevalence of Coronary Atherosclerosis in Patients With Fatal Stroke , 2007, Stroke.

[4]  C. Sudlow,et al.  Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. , 2005, Brain : a journal of neurology.

[5]  曲东锋.  Stroke Prevention by Aggressive Reduction in Cholesterol Levels , 2004 .

[6]  M. Cowan,et al.  American Heart Association. , 2018, P & T : a peer-reviewed journal for formulary management.

[7]  P. Wolf,et al.  American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. , 1997, Stroke.

[8]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[9]  M. Dyken,et al.  Stroke Risk Factors , 1991 .

[10]  S. Sidney,et al.  Short-term prognosis after emergency department diagnosis of TIA. , 2000, JAMA.

[11]  R. Sacco,et al.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[12]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[13]  S. Gutnikov,et al.  Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison , 2007, The Lancet.

[14]  W M O'Fallon,et al.  Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. , 2000, Stroke.

[15]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[16]  P. Wolf,et al.  Risk factors : Prevention and Rehabilitation of Stroke , 1997 .

[17]  C. Kase,et al.  American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Etiology of stroke. , 1997, Stroke.

[18]  David B. Matchar,et al.  Improving the Reliability of Stroke Subgroup Classification Using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Criteria , 2001, Stroke.

[19]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[20]  P. Touboul,et al.  A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects , 2007, The Lancet Neurology.

[21]  Cathy M. Helgason,et al.  American Heart Association Prevention Conference IV: Prevention and Rehabilitation of Stroke Introduction , 1997 .

[22]  Kam-Wing Ng,et al.  Improving Reliability for , 2010 .

[23]  M. Hennerici,et al.  Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial , 2007, Stroke.

[24]  Panel,et al.  Etiology of Stroke , 1997 .

[25]  E. Roth,et al.  American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Rehabilitation. , 1997, Stroke.